Jazz Pharmaceuticals, Inc. (JAZZ) Stock Price
JAZZStock
$210.23+56.60%52W
Market Cap$13.65B
P/E19.93x
PEG Ratio0.96
Div yield—
Beta0.38
JAZZ Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-5.34%
Price vs S&P 500 (4W)-11.61%
PEG Ratio0.96
VGM Score59.38
P/E Ratio (Annual)19.93x
JAZZ Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $6.18 | $5.71 | -7.54%(-$0.47) | |
| Q1 2026 | $4.66 | $6.34 | +36.18%(+$1.68) | |
| Q4 2025 | $6.51 | $6.64 | +2.05%(+$0.13) | |
| Q3 2025 | $5.85 | $8.13 | +38.97%(+$2.28) | |
| Q2 2025 | -$6.25 | -$8.25 | -32.07%(-$2.00) |
JAZZ Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.24
4.20
4.19
4.19
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
JAZZJazz Pharmaceuticals, Inc. | B | C | B | 3.0x | 12.6% | 88.4% | -1.4% | $210.23 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical company with approved treatments in neuroscience and oncology. Its portfolio of nine drugs includes leading franchises such as Xyrem/Xywav for narcolepsy, Epidiolex for severe epilepsy (acquired in 2021 from GW Pharmaceuticals), and oncology medications including Zepzelca, Rylaze, and Vyxeos. The company focuses on high-unmet-need therapeutic areas with limited competitive options.